InvestorsHub Logo
Followers 6
Posts 1400
Boards Moderated 0
Alias Born 08/24/2014

Re: ignatiusrielly35 post# 46815

Tuesday, 05/21/2019 10:30:02 AM

Tuesday, May 21, 2019 10:30:02 AM

Post# of 48316
In the Oncosec TNBC pilot study 2 patients had a robust response when a checkpoint was added to their therapy. 1 patient relapsed but the other patient did not. So out of 2 patients, ONCS had a 50% response rate. This was exciting enough to get Merck to agree to a second keynote study with Oncosec. Preliminary data for the Phase II study now in progress will be out soon. It is a strong catalyst for the stock.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ONCSQ News